Home Blog Page 9

Novo Nordisk Shares Slide After Trial Miss

CagriSema Falls Short of Expectations

Shares of Novo Nordisk dropped sharply after late-stage clinical trial results for its next-generation weight-loss drug, CagriSema, failed to meet investor expectations. The Danish pharmaceutical company saw its stock fall 16.5% in Copenhagen, marking its lowest level since mid-2021.

CagriSema is a weekly injection combining cagrilintide, an amylin analogue, with semaglutide, the active ingredient in Wegovy and Ozempic. The dual-hormone approach was designed to enhance weight reduction beyond semaglutide alone.

However, in a study involving 809 participants over 84 weeks, CagriSema achieved average weight loss of 23%, below the initially anticipated 25% and trailing Eli Lilly’s tirzepatide-based Zepbound, which posted 25.5% weight loss in comparable data.

Novo acknowledged that CagriSema did not meet its primary endpoint of demonstrating non-inferiority to tirzepatide on weight reduction after 84 weeks.

Market Reaction and Competitive Pressure

Analysts described the outcome as a significant disappointment. Some characterized the drug as less competitive than expected, particularly as an upgrade to semaglutide or as an alternative to Lilly’s leading therapy.

Novo’s stock decline extended a challenging period for the company. Over the past year, shares have fallen nearly 60%, while Eli Lilly’s stock rose more than 4% following the trial update.

Once Europe’s most valuable company on the back of booming obesity and diabetes drug sales, Novo has revised profit and revenue forecasts multiple times amid intensifying competition in the GLP-1 market.

Sales Outlook and Regulatory Path

Earlier this year, UBS reduced its peak sales forecast for Novo’s GLP-1 portfolio from $80 billion to $75 billion by 2032, citing earlier underwhelming data from CagriSema trials.

Despite the setback, Novo management defended the therapy. Chief Executive Mike Doustdar said the drug remains a strong candidate, emphasizing its position as the first amylin-based obesity treatment if approved. The company has already submitted CagriSema to U.S. regulators based on prior clinical evidence and is seeking approval later this year.

Novo also plans additional studies, including trials of higher dosing, to potentially demonstrate improved outcomes. The company is counting on both CagriSema and a newly launched oral version of Wegovy in the United States to regain competitive momentum.

Weight-Loss Market Intensifies

The obesity drug market has become one of the most competitive segments in pharmaceuticals, with GLP-1 and dual-hormone therapies driving investor interest. As companies race to deliver greater efficacy and more convenient delivery options, even small differences in clinical results can significantly influence market perception and valuation.

Whether CagriSema ultimately secures regulatory approval and meaningful commercial traction may depend on forthcoming data and how it positions itself against established rivals in a rapidly expanding global market.

Pakistan Strikes Near Afghan Border, Tensions Rise

Islamabad Says Dozens of Militants Killed

Pakistan’s military carried out airstrikes along the border with Afghanistan early Sunday, targeting what officials described as hideouts of Pakistani militant groups. Deputy Interior Minister Talal Chaudhry told local media that at least 70 militants were killed, while state-run outlets later reported the toll could be as high as 80. No independent evidence was immediately provided.

Information Minister Attaullah Tarar said the operation targeted seven camps linked to the Tehrik-e-Taliban Pakistan (TTP) and its affiliates, as well as an affiliate of the Islamic State group. He characterized the action as intelligence-based and selective, emphasizing that Pakistan’s top priority remains the security of its citizens.

Kabul Condemns Civilian Casualties

Afghanistan’s defense ministry said multiple civilian areas in Nangarhar and Paktika provinces were hit, including a religious madrassa and residential homes. The ministry described the strikes as a violation of Afghan airspace and sovereignty.

Government spokesperson Zabihullah Mujahid said dozens were killed or wounded, including women and children. Mawlawi Fazl Rahman Fayyaz of the Afghan Red Crescent Society in Nangarhar reported 18 confirmed deaths and additional injuries.

Local residents were seen clearing rubble and preparing funerals. Tribal elder Habib Ullah said those killed were ordinary villagers and not affiliated with militant groups.

Diplomatic Fallout and Protest

Afghanistan’s foreign ministry summoned Pakistan’s ambassador to Kabul, delivering a formal protest note. The ministry warned that protecting Afghan territory is a sovereign responsibility and said Pakistan would bear responsibility for consequences arising from the strikes.

Islamabad maintains that militant violence inside Pakistan has surged in recent years, blaming attacks on the TTP and allied groups. Pakistani officials allege these militants operate from Afghan territory, a claim denied by both the TTP and Afghanistan’s Taliban authorities.

Escalation After Suicide Attacks

The cross-border strikes followed a suicide bombing in Pakistan’s Bannu district that killed two soldiers, including a lieutenant colonel. Days earlier, an explosives-laden vehicle targeted a security post in Bajaur district, killing 11 soldiers and a child. Pakistani authorities said the Bajaur attacker was an Afghan national.

Tarar stated that Pakistan possesses what he described as conclusive evidence linking recent attacks, including a deadly bombing at a Shiite mosque in Islamabad, to Afghanistan-based militant leadership. He urged international pressure on Kabul to prevent militant groups from using Afghan territory to launch attacks, referencing commitments made under the Doha agreement.

Fragile Truce at Risk

The latest escalation threatens a fragile ceasefire brokered after deadly border clashes in October. Mediation efforts led by Qatar, Turkey and Saudi Arabia have so far failed to produce a lasting agreement.

Security analysts warn that renewed strikes could deepen instability between Islamabad and Kabul, adding further strain to already tense bilateral relations along one of South Asia’s most volatile borders.

Galaxy Buds 4 Dummies Leak Before Unpacked

First Look at Buds 4 and Buds 4 Pro

Samsung appears poised to unveil a new generation of wireless earbuds alongside the upcoming Galaxy S26 series, and early dummy units are already circulating ahead of next week’s Galaxy Unpacked event.

Photos shared by TechTalkTV on social media show non-functional display models of both the Galaxy Buds 4 and Galaxy Buds 4 Pro being distributed to retail stores. While these units do not power on, they offer a clear preview of the final design language expected at launch.

The images largely align with recent leaks, confirming that Samsung is continuing with a stem-based design. However, the addition of a metallic accent along the stem stands out as the most notable change.

Design Tweaks and Metallic Finish

The new silver-on-black finish seen on the Galaxy Buds 4 Pro suggests a more premium aesthetic compared to the standard model. The metallic plate along the stem appears to be a deliberate refinement, potentially responding to earlier comparisons between previous Galaxy Buds and Apple’s AirPods.

The Pro variant also returns to a square-shaped charging case rather than a flip-top design, helping differentiate it visually. In contrast, the standard Galaxy Buds 4 appear simpler and more understated, with some observers describing the look as reminiscent of older budget earbuds.

When viewed without the metallic detailing, both models still resemble Apple’s stemmed earbuds. However, visible charging connectors and the darker color option on the Pro version help reduce direct visual similarity.

Case Details and Extra Features

A rear view of the standard Galaxy Buds 4 case reveals a USB-C charging port and a physical sync button. The button may support pairing functions or potentially enable remote device-locating features, such as ringing a misplaced phone.

Because these display units are already being sent to retail partners, it is widely expected that Samsung will formally introduce both the Galaxy Buds 4 and Galaxy Buds 4 Pro at its upcoming Unpacked event next week.

FDA Agrees to Review Moderna mRNA Flu Shot

Agency Reverses Initial Refusal

The U.S. Food and Drug Administration will move forward with reviewing Moderna’s new mRNA-based seasonal flu vaccine after previously declining to accept the company’s application, Moderna announced Wednesday.

Earlier this month, the FDA sent Moderna a letter stating it would not accept the filing for review, citing concerns that the application did not include an “adequate and well-controlled” trial. According to the letter, the control arm of the study did not reflect the “best-available standard of care in the United States at the time of the study.”

The agency did not raise safety or efficacy concerns in its communication, Moderna said.

Revised Regulatory Pathway

Following discussions with regulators, Moderna proposed what it described as a revised regulatory strategy. Under the updated approach, the company is seeking full approval for adults ages 50 to 64 and accelerated approval for adults 65 and older. The accelerated pathway would require a post-marketing study focused on older adults.

The FDA has accepted the amended application. Andrew Nixon, spokesperson for the U.S. Department of Health and Human Services, said in a statement that discussions led to a revised regulatory approach and that the agency “will maintain its high standards during review and potential licensure stages as it does with all products.”

Potential Availability for 2026-2027 Season

If approved, the vaccine could be available for individuals 50 years and older during the 2026-2027 flu season.

Moderna had previously described the FDA’s initial refusal as inconsistent with earlier agency feedback. CEO Stéphane Bancel said the company appreciated the FDA’s engagement during a Type A meeting and its decision to advance the application for review.

“Pending FDA approval, we look forward to making our flu vaccine available later this year so that America’s seniors have access to a new option to protect themselves against flu,” Bancel said.

Rhythmic Raises $4M to Bring Stablecoins to Brands

Former Payments Executives Target Mainstream Adoption

As stablecoins gain traction in the broader financial system, two former credit card executives are betting the technology has yet to reach everyday consumers. Aaron Marks and Joseph Hayes have launched Rhythmic, a startup aimed at embedding stablecoin infrastructure directly into consumer brands’ financial products.

On Thursday, the company announced it raised $4 million in seed funding led by Dragonfly, with participation from Mirana Ventures, The Fintech Fund and other investors. Marks, Rhythmic’s co-founder and CEO, declined to disclose the company’s valuation.

The founders argue that stablecoins remain largely concentrated among crypto-native users and individuals in emerging markets. Rhythmic’s approach is to bring the technology into familiar environments by partnering with established brands.

“We are giving everyday users the power of stablecoins through brands that they already know and trust,” said Hayes, the company’s co-founder and chief product and technology officer. He added that the goal is to embed stablecoin-based financial services into widely used consumer ecosystems.

Rewards, Payments and Stored Value Accounts

Rhythmic plans to collaborate with medium and large consumer-facing companies to build integrated financial products that include stored balances, payments and rewards programs. The company envisions brands offering features similar to the Starbucks loyalty program or Walmart’s OnePay credit card, but with lower operational complexity and costs.

Under the model, users would deposit funds into a stored-value account embedded within a brand’s ecosystem. Customers would receive a co-branded Visa card and earn rewards through their spending. Stablecoins would operate behind the scenes to facilitate money movement and settlement, though users may not directly interact with the underlying crypto infrastructure.

The company did not name specific brand partners but said it is actively targeting mid-sized and large firms with established customer bases.

Blending Payments Experience With Crypto Infrastructure

Marks and Hayes bring experience from both traditional payments and digital assets. Marks previously worked at American Express for more than five years before joining Circle, a major stablecoin issuer. Hayes spent over eight years at Mastercard and later led crypto and stablecoin product initiatives at Walmart.

The founders believe this mix of payments expertise and crypto product development positions them to design stablecoin-powered services that feel familiar and accessible to mainstream users.

Rhythmic aims to launch its platform by midyear. The startup currently has no revenue and until recently operated with just three employees. It plans to expand to roughly six employees by the end of the month.

The new funding will support product development, hiring and investment in regulatory compliance as the company prepares to scale.

Study Finds Higher Prenatal PFAS Exposure Than Expected

New Testing Reveals Widespread “Forever Chemical” Exposure

Babies born between 2003 and 2006 were exposed in the womb to significantly more “forever chemicals” than previously estimated, according to a new study published February 18 in Environmental Science & Technology.

The chemicals, known as per- and polyfluoroalkyl substances (PFAS), include thousands of synthetic compounds still widely used in consumer and industrial products. Because scientists do not yet fully understand their long-term health effects, accurately measuring prenatal exposure remains a priority.

The research was led by Shelley H. Liu, PhD, Associate Professor of Population Health Science and Policy at the Icahn School of Medicine at Mount Sinai. Her team developed a data-driven approach to estimate newborn PFAS exposure using advanced chemical detection tools on umbilical cord blood samples.

PFAS are found in products such as nonstick cookware, stain-resistant fabrics, food packaging and firefighting foam. They are often called “forever chemicals” because they degrade very slowly and accumulate in the environment and in human bodies over time.

Advanced Analysis Identifies Dozens of Compounds

The researchers analyzed stored umbilical cord blood collected between 2003 and 2006 from 120 infants enrolled in the Cincinnati-based HOME Study. Since those children are now adolescents, future research can examine potential long-term health effects.

Instead of relying on traditional testing panels that target a limited list of known chemicals, the team used a non-targeted chemical analysis method capable of screening hundreds or thousands of substances simultaneously. This broader approach detected many more PFAS compounds than standard screenings typically identify.

In total, the team identified 42 confirmed or suspected PFAS chemicals in the cord blood samples, including newer and less studied compounds. These included perfluorinated chemicals, polyfluorinated chemicals and fluorotelomers, many of which are not routinely measured in clinical or environmental assessments.

Developing a PFAS “Burden Score”

To estimate overall exposure, the researchers created PFAS-omics burden scores using item response theory methods. These scores provide a cumulative snapshot of a newborn’s PFAS exposure at a single point in time.

When applying this comprehensive measurement, the team did not observe differences in PFAS exposure between first-time mothers and those with previous pregnancies. Earlier studies using narrower chemical panels had suggested such variations.

“When we look more comprehensively, we see that babies are exposed to far more PFAS chemicals before birth than we previously realized,” Liu said. She added that broader measurement methods may alter previously understood exposure patterns.

Health Implications and Future Research

Pregnancy is a sensitive developmental window. Prior research has associated prenatal PFAS exposure with lower birth weight, preterm birth, altered immune responses, metabolic changes and other developmental concerns.

Although exposure to PFAS is not routinely evaluated in clinical practice, the study’s methodology may eventually help clinicians identify individuals with higher cumulative exposure, monitor at-risk populations and guide preventive strategies.

The research team plans to investigate whether higher early-life PFAS burden scores are associated with adverse health outcomes as children age. They also aim to examine newly identified compounds and refine tools that support environmental risk prevention.

Perplexity Shifts Toward Subscriptions

Startup Prioritizes Revenue Over Growth Metrics

Perplexity is accelerating its push into subscriptions and enterprise sales, signaling a stronger emphasis on monetization as it matures in the competitive AI search market. Company executives said Monday that revenue growth and retention will now take precedence over headline metrics such as total queries answered.

The San Francisco-based startup has experienced rapid expansion over the past year, reporting that revenue increased 4.7 times during that period. By mid-2025, Perplexity had surpassed $150 million in annual recurring revenue (ARR), according to company leadership, and later reached $200 million in ARR by October.

Despite this growth, executives declined to provide updated financial details at a roundtable with reporters. They emphasized instead a strategic shift toward sustainable business performance.

No Immediate Plans for Advertising

Unlike some competitors in the generative AI space, Perplexity is not actively pursuing advertising deals within its chatbot interface. An executive said the company is not currently exploring ad partnerships, distancing the firm from models that integrate sponsored content into AI-generated answers.

The decision contrasts with OpenAI’s increasing openness to advertising experiments, while rival Anthropic has publicly maintained resistance to ad-based monetization. Perplexity had previously announced plans in 2024 to test ads, but that initiative stalled, and its advertising lead departed quietly last year.

Executives acknowledged a key challenge: users may distrust AI responses that contain promotional material. Maintaining credibility, they suggested, is central to long-term adoption.

Enterprise Push Intensifies

Perplexity is also expanding its focus on enterprise customers. The company currently has a five-person enterprise sales team but plans to grow that function significantly. Executives said they are targeting large organizations and high-powered professionals, including finance specialists, physicians and corporate executives.

This shift positions Perplexity more directly against companies such as Glean, which provides AI-powered internal search tools for businesses. In 2024, Perplexity introduced an enterprise product capable of generating research reports by integrating both internal corporate data and external sources.

While the company pledged to maintain a free version of its service with usage limits, the emphasis is clearly on subscription tiers and long-term contracts with businesses.

Facing Investor Skepticism

The renewed monetization focus comes amid skepticism in some venture capital circles. At an AI industry conference last year, Silicon Valley investors informally identified Perplexity as the startup they would most likely bet against, reflecting broader concerns about valuation levels and the possibility of an AI market bubble.

Executives suggested that in recent months the company has intentionally kept a lower profile, concentrating on product development rather than industry debates. The leadership framed the current pivot as a natural progression from rapid growth to disciplined execution.

Vatican Declines Trump’s ‘Board of Peace’

Holy See Cites Concerns Over Mandate

The Vatican will not join U.S. President Donald Trump’s proposed “Board of Peace,” according to Cardinal Pietro Parolin, the Holy See’s Secretary of State. Speaking to reporters on Tuesday, Parolin said the Vatican had been left “perplexed” by elements of the initiative and believed key issues remained unresolved.

The board, chaired indefinitely by Trump, was initially conceived to oversee reconstruction efforts in Gaza. Its mandate has since expanded into what organizers describe as a broader global peacekeeping platform. Pope Leo XIV had received an invitation to participate last month.

Parolin indicated that the Vatican’s reservations center on institutional legitimacy and international governance. “At the international level it should above all be the UN that manages these crisis situations,” he said, emphasizing the Holy See’s longstanding position that the United Nations should remain the primary forum for global conflict management.

UN Role Emphasized

The cardinal’s remarks came during an event marking the anniversary of the Lateran Pacts, which established Vatican City as a sovereign state. He added that the Holy See would not participate in the board due to its “particular nature,” suggesting it differs from traditional intergovernmental frameworks.

Several other countries have also declined to join the initiative. Britain, France and Norway have opted out, while Italy and the European Union plan to attend as observers. Diplomats and international officials have raised concerns about the board’s expanded remit, Trump’s indefinite leadership role and potential overlap with existing UN functions.

Pope Leo’s Diplomatic Priorities

Pope Leo XIV, the first U.S.-born pontiff, has made peacemaking central to his papacy. In a recent diplomatic address, he warned that “war is back in vogue” and reiterated that the UN “should play a key role” in resolving conflicts while upholding humanitarian law.

Since his election, Leo has repeatedly addressed the conflict in Gaza, calling for a two-state solution and advocating for Palestinians’ right to live peacefully “in their own land.” He has also urged the release of hostages taken during the October 7 attacks, maintained dialogue with Israeli leaders and condemned rising antisemitism.

The pope’s emphasis on international law contrasts with Trump’s more unilateral approach. In a January interview with The New York Times, Trump suggested he feels constrained primarily by his “own morality,” dismissing aspects of the post-World War II international order.

First Meeting Set for Washington

The Board of Peace is scheduled to convene for its inaugural meeting in Washington on Thursday. While the Vatican’s decision underscores its cautious stance toward the initiative, the broader diplomatic debate over the board’s legitimacy and scope is likely to continue as governments assess its role alongside established multilateral institutions.

GameSir Bringing Windows Emulation to Mac

GameSir Bringing Windows Emulation to Mac

Android Tool Expands to macOS

Mac users have increasingly relied on tools such as CrossOver and Apple’s Game Porting Toolkit to run Windows games. Now, gaming peripheral maker GameSir says it plans to introduce its own alternative for macOS, expanding its existing Windows emulation software from Android to Apple computers.

The Hong Kong-based company is best known for its controllers and accessories, branding itself online as an “Anti-Stick Drift” specialist. In early 2024, however, GameSir entered the software arena with its Android GameHub app. The app includes a Windows emulation layer called GameFusion, which the company claims allows Windows games to run on Android devices through a high-precision compatibility system.

Performance on Android has produced mixed results. Users on Reddit and gaming forums report inconsistent compatibility, particularly with major Steam titles. Some indie games built on engines such as Unity, Godot or Game Maker reportedly work reliably, while others show frequent crashes or poor performance.

Promises for Mac Gamers

GameSir now says a macOS version is “coming soon,” promoting the ability to unlock entire Steam libraries and run Windows titles directly on a Mac. The company is also advertising proprietary AI-based frame interpolation for smoother performance. This follows an earlier “native rendering mode” update on Android that aimed to improve frame rates.

If successful, the Mac version could offer another route for users who prefer not to install Windows or rely solely on Apple’s official development tools. Apple gaming has seen incremental progress in recent years, but many Windows titles still lack native Mac support.

Motivations and Concerns

In an interview with The Memory Core newsletter, GameSir acknowledged that expanding into Windows emulation was partly intended to drive sales of its controllers. That said, GameHub on Android does not require a GameSir controller to function. According to the company, the app had already been sideloaded onto millions of Android devices before its official Google Play launch in November.

The Android version has faced criticism for including tracking components, which were later removed in a community-built Lite edition. A company representative described the tracking as standard practice in certain markets and stated it has since been eliminated.

Questions have also arisen regarding the software’s technical foundations. GameSir maintains that GameFusion was built in-house, using its own compatibility layer rather than modifying Wine’s core code. However, the company has acknowledged referencing user interface elements from Winlator, an open-source Windows emulator for Android.

Another Option, Not a Revolution

Given its uneven track record on Android and lingering concerns over transparency, GameSir’s Mac offering may not represent a transformative breakthrough for Apple gaming. Still, for Mac owners seeking additional ways to access Windows-only titles, it could provide another experimental avenue without requiring a separate Windows installation.

Air Pollution Tied to Higher Alzheimer’s Risk

Air Pollution Tied to Higher Alzheimer’s Risk

Large U.S. Study Examines Long-Term Exposure

Long-term exposure to fine air pollution particles is associated with a higher risk of developing Alzheimer’s disease, according to new research examining data from tens of millions of older Americans.

The study, conducted by scientists at Emory University in Georgia and published in Plos Medicine, analyzed health and location records from 28 million people aged 65 and older between 2000 and 2018. Researchers found that dementia rates were higher in postal areas with greater concentrations of fine particulate matter, commonly known as PM2.5.

These microscopic particles are primarily produced by fossil fuel combustion, including vehicle exhaust, industrial activity and wildfires. On average, study participants were exposed to pollution levels roughly double the annual limit recommended by the World Health Organization.

Potential Direct Effects on the Brain

The findings suggest that polluted air may influence brain health more directly than previously understood. While people living in more polluted areas were more likely to develop conditions such as hypertension, stroke and depression — all recognized dementia risk factors — most additional Alzheimer’s cases appeared independent of these chronic illnesses.

This pattern raises the possibility that air pollution itself could play a more direct role in the development of dementia, though the study does not prove causation.

Mark Dallas, associate professor of cellular neuroscience at the University of Reading, said the research reinforces the idea that long-term exposure to polluted air can influence how the brain ages.

Scientific Debate and Limitations

Independent experts welcomed the scale of the study but noted its limitations. Pollution exposure was estimated based on postcode-level data rather than individual monitoring. Other risk factors, such as smoking status or weight, were also approximated using broader geographic data.

Professor Eef Hogervorst of Loughborough University said that cardiovascular and other pollution-related health conditions explain only part of the dementia link. She pointed to emerging evidence suggesting that pollution may contribute to toxic plaque buildup in the brain or inflammation of nervous tissue. Some recent studies have also connected air pollution to the formation of abnormal protein clumps known as Lewy bodies.

Policy and Public Health Context

The findings come amid shifting regulatory policy in the United States. The Environmental Protection Agency recently moved to soften certain federal air pollution limits, and President Donald Trump revoked a previous ruling that supported the agency’s authority to regulate greenhouse gas emissions.

Researchers and public health experts say the growing body of evidence underscores the broader health implications of air quality, not only for dementia but also for other serious illnesses linked to long-term exposure.

Hogervorst emphasized that policymakers and individuals alike should recognize pollution as a factor affecting both longevity and quality of life.